Medically reviewed by Nachiket J. Patel, MD, FACC, FSCAI. Last medically reviewed: August 2026.
A deep vein thrombosis, or DVT, is usually treated with an anticoagulant. Starting the medication is only the first decision.
Follow-up should confirm that treatment is safe, clarify what may have contributed to the clot, decide how long protection is needed, and address leg symptoms that may continue after the acute event. It also creates a plan for surgery, travel, pregnancy, or another situation that may change clotting risk later.
The details differ for a clot below the knee, a proximal leg clot, an arm DVT, a pregnancy-associated event, a cancer-associated clot, and a DVT accompanied by pulmonary embolism. A discharge instruction sheet cannot settle every one of those questions.
First: make anticoagulation safe and workable
Anticoagulants keep an existing clot from enlarging and reduce the chance of another clot while the body gradually reorganizes the original one. They do not usually make leg swelling disappear overnight.
Early follow-up commonly reviews:
- The exact drug, dose, and dosing schedule
- Missed doses and whether cost or access is creating gaps
- Kidney and liver function when relevant to the medication
- Other prescriptions, aspirin, anti-inflammatory medicines, and supplements that may increase bleeding or interact
- Bruising, menstrual bleeding, blood in urine or stool, and any falls or injuries
- Planned dental work, surgery, injections, or procedures
Do not stop an anticoagulant because the leg feels better or because a refill runs out. A short interruption can matter. Call the prescribing team before changing a dose, and ask for help early if coverage or pharmacy access is a problem.
The cause helps frame the duration
Clinicians usually ask whether the DVT followed a major temporary risk—such as surgery, trauma, hospitalization, or prolonged immobility—or occurred without a clear transient trigger. They also review active cancer, pregnancy or the postpartum period, estrogen exposure, prior clots, family history, clot location, and ongoing medical conditions.
Guidelines describe an initial treatment phase measured in months, not days. Many patients receive three to six months of primary treatment. Some then stop; others continue extended anticoagulation because recurrence risk remains important. Bleeding risk and patient preferences must be reassessed alongside clot risk.
“Unprovoked” does not automatically mean lifelong medication, and “provoked” does not mean every patient stops on the same date. The decision should be made deliberately before the prescription ends.
A repeat ultrasound is not always required
Patients often expect an ultrasound to prove that the clot has vanished. Residual material can remain visible after effective treatment and may represent chronic change rather than active treatment failure.
The American Society of Hematology advises against routinely using residual-vein ultrasound, a D-dimer, or a prediction score as the sole method for deciding anticoagulation duration after an unprovoked event. Repeat vascular ultrasound may still be appropriate when symptoms worsen, the original study was limited, a new clot is suspected, or the result would answer a specific management question.
Imaging should be ordered because it can change the plan—not merely to obtain a more reassuring picture.
Leg symptoms may outlast the acute clot
Swelling, aching, heaviness, skin discoloration, or discomfort after standing can continue. Some patients develop post-thrombotic syndrome because the clot and inflammation have damaged venous valves and increased pressure in the leg.
Follow-up should distinguish expected gradual improvement from recurrent DVT, infection, arterial disease, medication-related swelling, or chronic venous obstruction. Helpful measures may include regular walking as tolerated, leg elevation, weight management when appropriate, and skin care.
Compression stockings are not recommended routinely for every patient solely to prevent post-thrombotic syndrome. They may help selected patients with swelling or discomfort when the size and compression level are appropriate. A painful, poorly fitting stocking is not a successful treatment.
New skin breakdown, persistent discoloration, or a wound that is not healing deserves assessment rather than prolonged self-treatment.
Thrombophilia testing is selective
A large inherited-clotting panel is not automatically useful after every DVT. Testing is more likely to affect care in selected situations—for example, thrombosis at an unusual site, recurrent events, a strong family history, younger age, or concern for antiphospholipid syndrome.
Timing matters because an acute clot and some anticoagulants can distort test results. Testing that cannot change treatment may add cost and confusion. The 2023 ASH guideline uses specific clinical scenarios rather than recommending broad routine screening.
Build a plan for the next risk period
Before a long trip, operation, hospitalization, pregnancy, or a new estrogen-containing medication, tell the treating clinician about the DVT. Ask who will manage anticoagulant interruption and restart if a procedure is planned. Do not create a “bridging” plan yourself.
Keep an up-to-date medication list and know which clinician owns the duration decision. If follow-up is divided among several offices, the plan should still be explicit.
Symptoms that need urgent or emergency care
Call 911 for sudden unexplained shortness of breath, chest pain—especially pain worse with a deep breath—coughing up blood, fainting, severe lightheadedness, or a new rapid or irregular heartbeat. These can be signs of a pulmonary embolism.
While taking an anticoagulant, call 911 for uncontrolled bleeding, vomiting blood, a severe sudden headache, significant head injury with concerning symptoms, fainting, or severe weakness. Contact the clinical team promptly for new one-sided swelling, pain, warmth, or discoloration, even if you are still taking medication.
Sources and Further Reading
- Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Blood Advances. 2020;4:4693–4738. ASH notes that the guideline remains under annual evidence monitoring.
- Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. ASH 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing. Blood Advances. 2023.
- Centers for Disease Control and Prevention. About Venous Thromboembolism. Updated March 5, 2025.
- Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC Multisociety Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. J Am Coll Cardiol. 2026.
Related heart and vascular information
Schedule an appointment
If you would like a focused review of your symptoms, risk, testing, or treatment options, request an appointment with Flow Heart & Vascular in Mesa, Arizona.
This article provides general education and does not replace individualized medical advice, diagnosis, or emergency care. Do not start, stop, or change medication or delay emergency care based only on information on this website.
